HC Wainwright & Co. Maintains Buy on Oncolytics Biotech, Maintains $5 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Patrick Trucchio has maintained a Buy rating on Oncolytics Biotech (NASDAQ:ONCY) with a $5 price target, indicating a positive outlook on the company's stock.
March 08, 2024 | 6:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. maintains a Buy rating on Oncolytics Biotech with a $5 price target, suggesting confidence in the company's future performance.
The maintenance of a Buy rating and a $5 price target by a reputable analyst firm like HC Wainwright & Co. indicates a strong belief in the potential growth and value of Oncolytics Biotech. This positive analyst outlook can influence investor sentiment and potentially lead to an increase in stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100